Blockade of Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and Programmed Cell Death Protein 1 (PD-1) significantly improves progression-free survival in patients with cancers, including melanoma. Here, CTLA4 is linked to melanoma.